Common Side Effects of Wegovy
Wegovy, a brand name for the active ingredient semaglutide, is a medication approved for weight management and type 2 diabetes treatment [1]. As with any prescription medication, patients may experience side effects. We will discuss the potential connection between Wegovy and diarrhea.
What are the chances of experiencing diarrhea with Wegovy?
According to the FDA-approved labeling for Wegovy, gastrointestinal side effects, including diarrhea, are common [2]. In clinical trials, the incidence of diarrhea was 24.4% for patients taking Wegovy compared to 9.2% for those on a placebo.
Risk factors that increase the likelihood of diarrhea with Wegovy
Several factors can increase the risk of experiencing diarrhea while taking Wegovy:
- Higher doses: Patients on higher doses of Wegovy (2.4 mg once weekly) had a higher incidence of gastrointestinal side effects, including diarrhea [3].
- Combination therapy: When used in combination with other medications, such as metformin (Glucophage), the risk of gastrointestinal side effects may increase.
- Underlying medical conditions: Patients with pre-existing gastrointestinal conditions, such as gastroparesis, may be more susceptible to developing diarrhea while taking Wegovy.
- Age and renal impairment: Patients 65 years or older and those with mild renal impairment may experience a higher risk of gastrointestinal side effects, including diarrhea.
When to seek medical attention
If you experience persistent or severe diarrhea while taking Wegovy, notify your healthcare provider. They may be able to adjust your dosage, recommend alternatives, or provide guidance on managing symptoms.
Alternatives and management strategies
If you are concerned about the risk of diarrhea, discuss the following options with your healthcare provider:
- Other weight management medications: Your doctor may consider alternative medications or recommend lifestyle changes.
- Gradual dose escalation: Increasing the Wegovy dose gradually may help minimize gastrointestinal side effects.
References
[1] Novo Nordisk. (2022, August). Wegovy (semaglutide injection) 2.2 mg/mL, 2.4 mg/mL, 5 mg/mL; Solution. Retrieved on April 15, 2024, from https://www.drugs.com/pro/wegovy.html
[2] Novo Nordisk. (2022, August). Wegovy (semaglutide injection) 2.2 mg/mL, 2.4 mg/mL, 5 mg/mL; Solution. Retrieved on April 15, 2024, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210695Orig1s000lbl.pdf
[3] Wadden, T. A., et al. (2020, June). Once-Weekly Semaglutide in Adults with Obesity. New England Journal of Medicine. 382(21), 2053–2063, doi: 10.1056/NEJMoa2015464